Recruiting Trials of the GCLLSG
First-Line Therapies for CLL
Currently no recruiting trials for First-Line Therapy.
Therapies for relapsed/refractory CLL
- CLL2-BZAG
- A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL
- » more
Therapies for Richter Transformation
- CLL-RT1
- A prospective, open-label, multicenter phase-II trial to evaluate the
efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor, plus
tislelizumab (BGB-A317), a PD1 inhibitor, for treatment of patients
with Richter Transformation
- » more
Transplantation Trials
Currently no recruiting transplantation trials
-
